52768 Federal Register / Vol. 75, No. 166 / Friday, August 27, 2010 / Notices 

2FDA has verified the Web site address, but FDA 

is not responsible for any subsequent changes to the 

Web site after this document publishes in the 

Federal Register. 

Drug Administration, 5600 Fishers 

Lane, rm. 6–30, Rockville, MD 20857. 

VII. References 

1. ‘‘Useful Written Consumer 

Medication Information (CMI)’’ 

published in July 2006, available on the 

Internet at http://www.fda.gov/ 

downloads/Drugs/GuidanceCompliance

RegulatoryInformation/Guidances/ 

ucm080602.pdf. 

2. Kimberlin CL, Winterstein AG. 

‘‘Expert and Consumer Evaluation of 

Consumer Medication Information— 

2008.’’ Final Report to FDA. November 

2008 available on the Internet at http:// 

www.fda.gov/downloads/AboutFDA/ 

CentersOffices/CDER/ReportsBudgets/ 

UCM163783.pdf. 

3. FDA’s Risk Communication 

Advisory Committee meeting, held on 

February 26 and 27, 2009 (73 FR 74505, 

December 8, 2008), available on the 

Internet at http://www.fda.gov/ 

downloads/AdvisoryCommittees/ 

CommitteesMeetingMaterials/ 

RiskCommunication

AdvisoryCommittee/UCM152593.pdf. 

4. ‘‘Providing Effective Information to 

Consumers about Prescription Drug 

Risks and Benefits—The Issues Paper’’ 

from the 2009 public workshop 

available on the Internet at http:// 

www.fda.gov/downloads/Drugs/ 

NewsEvents/UCM182799.pdf. 

5. ‘‘Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Experimental Study 

of Patient Information Prototypes,’’ 

available on the Internet at2 http:// 

edocket.access.gpo.gov/2010/pdf/2010- 

10359.pdf 

Dated: August 23, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–21326 Filed 8–26–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0002] 

Withdrawal of Approval of New Animal 

Drug Applications; Dichlorophene and 

Toluene Capsules 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is withdrawing 

approval of two new animal drug 

applications (NADAs) for use of 

dichlorophene and toluene deworming 

capsules for cats and dogs. In a final 

rule published elsewhere in this issue of 

the Federal Register, FDA is amending 

the regulations to remove portions 

reflecting approval of these NADAs. 

DATES: Withdrawal of approval is 

effective September 7, 2010. 

FOR FURTHER INFORMATION CONTACT: John 

Bartkowiak, Center for Veterinary 

Medicine (HFV–212), Food and Drug 

Administration, 7519 Standish Pl., 

Rockville, MD 20855, 240–276–9079; 

email: john.bartkowiak@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Pegasus 

Laboratories, Inc., 8809 Ely Rd., 

Pensacola, FL 32514 has requested that 

FDA withdraw approval of NADA 101– 

497 for TINY TIGER (dichlorophene/ 

toluene) Worming Capsules, NADA 

101–498 for LK (dichlorophene/toluene) 

Worming Capsules because they are no 

longer manufactured or marketed. 

Therefore, under authority delegated 

to the Commissioner of Food and Drugs 

and redelegated to the Center for 

Veterinary Medicine, and in accordance 

with § 514.116 Notice of withdrawal of 

approval of application (21 CFR 

514.116), notice is given that approval 

of NADAs 101–497 and 101–498, and 

all supplements and amendments 

thereto, is hereby withdrawn, effective 

September 7, 2010. 

In a final rule published elsewhere in 

this issue of the Federal Register, FDA 

is amending the animal drug regulations 

to reflect the withdrawal of approval of 

these NADAs. 

Dated: August 23, 2010. 

Bernadette Dunham, 

Director, Center for Veterinary Medicine. 

[FR Doc. 2010–21295 Filed 8–26–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket No. DHS–2010–0071] 

National Protection and Programs 

Directorate; Agency Information 

Collection Activities: Office of 

Infrastructure Protection; Chemical 

Security Awareness Training Program 

AGENCY: National Protection and 

Programs Directorate, DHS. 

ACTION: 60-Day notice and request for 

comments. 

Extension of a Currently Approved 

Information Collection: 1670–0009. 

SUMMARY: The Department of Homeland 

Security, National Protection and 

Programs Directorate, Office of 

Infrastructure Protection, SectorSpecific Agency Executive Management 

Office (NPPD/SSA EMO), submits the 

following Information Collection 

Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and clearance in accordance 

with the Paperwork Reduction Act of 

1995 (Pub. L. 104–13, 44 U.S.C. Chapter 

35). 

DATES: Comments are encouraged and 

will be accepted until October 26, 2010. 

This process is conducted in accordance 

with 5 CFR 1320.1. 

ADDRESSES: Written comments and 

questions about this Information 

Collection Request should be forwarded 

to the Department of Homeland 

Security, NPPD/SSA EMO, Chemical 

Sector-Specific Agency, 245 Murray 

Lane, SW., Mail Stop 0608, Washington, 

DC 20528–0608. E-mailed requests 

should go to Amy Graydon at 

chemicalsector@dhs.gov. Written 

comments should reach the contact 

person listed no later than October 26, 

2010. Comments must be identified by 

DHS–2010–0071 and may be submitted 

by one of the following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. 

• E-mail: chemicalsector@dhs.gov. 

Include the docket number in the 

subject line of the message. 

Instructions: All submissions received 

must include the words ‘‘Department of 

Homeland Security’’ and the docket 

number for this action. Comments 

received will be posted without 

alteration at http://www.regulations.gov, 

including any personal information 

provided. 

SUPPLEMENTARY INFORMATION: The 

Chemical Sector-Specific Agency, 

within the DHS NPPD/SSA EMO, 

provides an on-line voluntary training 

program to improve security in the 

chemical industry sector. Information is 

automatically collected in a computer 

database as a result of individuals 

engaging in the training. Explicit 

reporting or recordkeeping is not 

required. The training is designed for 

the general chemical facility employee. 

U.S. chemical industry direct 

employment is about 850,000 (2009 per 

the American Chemistry Council); 

approximately 400,000 employees are 

estimated as potential participants. 

Estimated duration in the first year to 

complete the registration, training, and 

survey is 60 minutes, and less if 

individuals take refresher training in 

succeeding years. Minimal participation 

data is collected as trainees complete 

the online exercises. Upon completion, 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES